NEWS
Return
to the English home page ../index_ang.htm
Return
to the home page ../index.htm
Consultar la web en español http:www.imor.org
Consultar noticias en español contenido3_cast.htm
Consultar la web en català http://www.imor.org/index_cat.htm
Consultar noticies en català contenido3_cat.htm
Links related LINKS IMOR.htm
Currículo profesor Dr Benjamín
Guix MD PhD MBA Professor_Dr_Benjamin_Guix_CV.pdf
Profesor_Doctor_Benjamin_Guix_Melcior_CV_es.pdf
Profesor_Doctor_Benjamin_Guix_Melcior_CV_ct.pdf
Profesor_Dr_Benjam_n_Guix_CV.pdf
·
Brachytherapy beter thar surgery (prostatectomy) for
prostate cancer. An study
performed at Spain, published in the International Journal Radiation
Oncology-Biology-Physics that has been done under the co-ordination of IMOR Foundation, Medical Institute for
Radiotherapy and Oncology from Barcelona, concludes that long-term quality of life for patients with low-risk
prostate cancer is beter if they haven been treated by brachytherapy that if they were treated by surgery. For
intermediate- or high-risk prostate cancer the treatment with beter long-term
disease-free survival and quality of life is combined treatment with
brachytherapy and IMRT radiotherapy. 3
PROSTATE BRACHYTHERAPY QOL_IJROBP BENJAMIN GUIX.pdf
·
“For prostate cancer we have achieved
spectacular results”. In an
interview appeared at the Universal newspaper, Professor Doctor Benjamín Guix,
director of IMOR Foundation, Medical
Institute for Radiotherapy and Oncology from Barcelona explains the
advances in Radiotherapy and Brachytherapy, that have boosted cures for cancer
up to never-before seen levels to the majority of tumors. 2
UNIVERSAL NEWS IBERIA DR BENJAMIN GUIX.pdf
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology from
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology from Barcelona, presents the best treatment for prostate cancer. The event was hosted by Professors Dr Benjamin Guix Melcior, Director of the
IMOR Foundation, Medical Institute for Radiotherapy and Oncology of Barcelona,
Spain, Dr Jose Maria Bartrina, urologist and Dr Jose I Tello, physicist. Treatment
is high tech state of the art Image
Guided Intensity modulated Radiotherapy IGRT/IMRT with Brachytherapy, either
high-dose-rate or low-dose-rate (HDR LDR I125). Treatment is indicated for
patients with localized prostate cancer
and is done in an out-patient basis. The IMOR Foundation was the first centre
in Europe incorporating this technology and is one with the largest experience world-wide.
Treatment offers more than 98% cure for
prostate cancer. The results has been presented in the International
Meeting for Genyto-urinary cancer, held in San Francisco (USA).
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology from Barcelona, presents a revolutionary treatment for age related wet
macular degeneration (AMD). The The
event was hosted by Professors Dr. Borja
Corcóstegui, Director of the Ocular Microsurgery Institute (IMO) in Barcelona
and Dr Benjamin Guix Melcior, Director of the IMOR Foundation, Medical Institute
for Radiotherapy and Oncology of Barcelona, Spain, who are serving as a
principle investigator for the NeoVista sponsored CABERNET clinical study. Also
on the program were John N. Hendrick, President and CEO of NeoVista; Dr. Eugene
de Juan, vice chairman of ForSight Labs and co-inventor of the NeoVista
technology Brachytherapy in conjunction with the administration of lucentis is
the best treatment for AMD.
·
AMD is one of the most serious conditions that
affect the macula (the part of the eye responsible for central vision) and is
the main cause of irreparable blindness in people over 60. If left untreated,
the condition gives rise to a rapid loss of central best vision.
There are currently more than 164,000 people with wet AMD in Spain, and 30,000
new cases are detected every year. These figures are expected to increase in
the coming years as the population ages. NeoVista has begun a definitive
clinical trial called CABERNET (CNV
Secondary to AMD Treated with BEta RadiatioN Epiretinal Therapy) to demonstrate
the effectiveness of the NeoVista treatment protocol compared to the results
obtained with anti-VEGF therapy alone. This study will recruit 495 patients in
40 clinical sites throughout the world, including the Ocular Microsurgery
Institute (IMO) in Barcelona, which will begin its initial treatments in
February 2008. The IMOR Foundation and the IMO from Barcelona will be the only
Spanish centres treating patients in this extremely important trial. Dr Borja Corcostegui and Dr Benjamin Guix
Melcior will serve as principle investigators and responsible of the
project.
·
To learn more
about prostate cancer treatment by IGRT,
IMRT and Brachytherapy as best
treatment for cancer listen to some of the interview done to Dr Benjamin Guix Melcior, from the IMOR Foundation, Medical Institute for
Radiotherapy and Oncology of Barcelona, Spain, the best treatment for cancer abroad, cut and paste over the link:
http://profesional.medicinatv.com/webcast/muestra.asp?idfg=0&idwc=1387
·
The Combined
treatment Image-guided Intensity Modulated Radiotherapy (IG-IMRT) plus Prostate
Brachytherapy has been demonstrated to be the best approach for intermediate
and high risk prostate cancer, as
presented today at the World Congress of genito urinary cancer held at San
Francisco. The research has been carried-out at The IMOR Foundation, Medical Institute for Radiotherapy and Oncology,
from Barcelona, Spain, one of the top
place to have the best radiotherapy and
brachytherapy abroad, and has been presented by Professor Dr. Benjamin
Guix, MD PhD MBA.
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology, has been
invited to participate in the 13th Puerto Rico Breast Cancer Conference, to expose the recent
developments in the treatment of breast cancer and the future perspectives that
are now opened. Professor Dr Benjamin
Guix MD PhD MBA, Director of The IMOR Foundation, Medical Institute for
Radiotherapy and Oncology, from Barcelona, Spain, will present the
experience of The IMOR Foundation,
Medical Institute for Radiotherapy and Oncology, in partial breast
irradiation, salvage treatment and breast brachytherapy. The IMOR Foundation, Medical Institute for Radiotherapy and Oncology, has
one the best and longest series of patients treated with these advanced
treatments. The IMOR Foundation is considered one of the best place to have cancer treatment abroad and has been
awarded twice with the Best ESTRO
(European Society for Radiotherapy and Oncology) Award, in 2000 and 2007.
At the waterfront of the best treatment
for breast cancer.
·
The European
Society for Radiotherapy and Oncology (ESTRO) has awarded The IMOR Foundation,
Medical Institute for Radiotherapy and Oncology at Barcelona (Spain) with the
BEST BRACHYTHERAPY AWARD. The price was given to The IMOR Foundation for their
contribution to the development of conservative treatment for cancer, mainly prostate cancer. The treatment with brachytherapy, alone or in
combination with external beam radiotherapy, has been demonstrated to produce
the highest rates of cure, while
preserving the Quality of Life at the
best. The award was offered to Professor
Dr Benjamin Guix, MD PhD MBA, Director of The IMOR Foundation, Medical Institute for Radiotherapy and Oncology,
by the president of GEC-ESTRO, Erik Van
Limbergen, at a Gala Dinner held at Montpellier, during the Celebration of
the Annual ESTRO meeting. The IMOR Foundation, Medical Institute for Radiotherapy
and Oncology of Barcelona, Spain, is
considered one on the best place to have the treatment of cancer abroad.
·
IMRT-Brachytherapy
Combined treatment offers the best
long-term results in the treatment for intermediate- and high-risk prostate
cancer. The 16-year free-from-relapse survival rate was higher than 90%.
The results has been published in the International Journal of Radiation
Oncology Biology and employed the same protocol used at The IMOR Foundation, Medical Institute for Radiotherapy and Oncology from Barcelona, Sapin, since 1.999, said Professor
Dr
·
The IMOR Foundation,
Medical Institute for Radiotherapy and Oncology, from Barcelona (Spain),
starts treating patients with Image
Guided (IGRT) Intensity Modulated Radiotherapy (IMRT) IG-IMRT. This is the first
centre employing this technology of southern Europe. The IG-IMRT program is
directed by Professor Dr
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology, from Barcelona
(Spain), starts treating patients for prostate cancer with Image Guided (IGRT), Intensity Modulated Radiotherapy (IMRT) IG-IMRT,
the best and most precise way of radiotherapy and brachytherapy existing today,
announced Professor Dr
·
The IMOR
Foundation, Medical Institute for Radiotherapy and Oncology from Barcelona, Spain has begun the Image Guided Radiotherapy (IGRT), for
the first time in Spain, and southern Europe, announced its director Professor
·
Combined treatment with 3D- conformal Radiotherapy/ IGRT IMRT + Brachytherapy either with I-125
permanent implant or HDR temporal implant, is associated with excellent 3- and 5- year disease-free
survival rates in patients with clinically localized prostate cancer and high PSA levels. Data has been
presented by Dr
·
Dr Benjamin
Guix, Director of the IMOR Foundation, Medical Institute for Radiotherapy
and Oncology of Barcelona, Spain, has presented in the World Brachytherapy
Congress the long-term results of prostate brachytherapy for low- intermediate-
and high-risk prostate cancer. Results are really spectacular, with extremely
high disease-free survival and excellent quality of life. This is the best treatment for prostate cancer.
·
Dr Benjamin
Guix, Director of the IMOR Foundation presents the European experience in
prostate brachytherapy during the World Congress of Brachytherapy, the best
meeting of radiotherapy and brachytherapy.
·
Gynaecological
Brachytherapy considered as the standard
treatment for the best treatment for
gynaecologycal cancer, informed Dr Jose Antonio Lejarcegui and Professor Dr
·
Prostate
Brachytherapy, increases local control at the same time that decreases side-effects
in prostate cancer, as shown by a multi-center study, in which the contribution
of Doctors from The IMOR Foundation,
Medical Institute for Radiotherapy and Oncology from Barcelona, Sapin, has been very important,
that has been presented by Professor Dr
Benjamin Guix, Director of the IMOR Foundation at the ASCO 2005 ANNUAL MEETING (American Society for Clinical Oncology),
held at Chicago (USA). This treatment offers the best disease-free survival and the best quality of life for
prostate cancer.
·
Brachytherapy-only,
is
a highly effective treatment for breast recurrences. This data have been confirmed
by a trial conducted by scientifics from The
IMOR Foundation, Medical Institute for Radiotherapy and Oncology from Barcelona, Spain, presented by Professor Dr
Benjamin Guix, at the GEC-ESTRO European
Meeting on Brachytherapy, held at Lubeck (Germany), considered the best
brachytherapy meeting. Brachytherapy is the
most effective treatment for cancer.
·
Brachytherapy
offers more than 90 % local control in cancer. Professor Alain Gerbaulet,
former Head of the Brachytherapy Unit from Institute Gustav-Roussy, made this
assertion in the II International
Oncological Meeting, invited by Professor Dr Benjamin Guix Director of the IMOR
Foundation. Nowadays, brachytherapy offers the
best results for cancer treatment. The IMOR Foundation, Medical Institute for
Radiotherapy and Oncology of Barcelona, Spain, offers the highest technology
and the most experienced team for treating cancer abroad in southern
Europe.
·
The last 8th of april, IMOR Foundation, Medical Insitute for Radiotherapy and Oncology,
held the Ist International Conference
about Advances on Brachytherapy. World leaders in this effective and useful
form of cancer treatment discussed about the recent developments and
discoveries and the state of the art of this extraordinary technique. The
Conference was presided by the catalan minister of Health and Social Security
Mr. Xavier Pomés. By the IMOR Foundation, Medical Institute for Radiotherapy
and Oncology of Barcelona, Spain, presented their results Drs Antonio Arellano,
Ferran Guedea and Professor Dr Benjamin Guix and the physicist Jose Ignacio
Tello, about the best radiotherapy
treatment.
·
Brachytherapy
boost useful in early breast cancer. Stage I and II breast
tumors that are treated by a brachytherapy boost are doing better than those
patients without boost even if they have poor prognostic factors as positive
margins, extensive intraductal component or vascular invasion, according to a
consensus meeting held in Barcelona. Results confirm the IMOR Foundation
long-term experience, presented by Professor Dr
·
Local relapses
after conservative treatment for breast cancer, can be safely managed without
mastectomy by means of brachytherapy-only, as a phase II study
presented by Professor Dr
·
Temporary PSA bounces has no significant prognostic
importance, as confirmed by a paper published in the International Journal of
Radiation Oncology Biology and Physics, Dr
·
Partial Breast
Irradiation (PBI) by Brachytherapy-only very effective treatment for early
stage breast cancer. Differents reports appeared in the Journal of
Clinical Oncology confirm that PBI is a very effective treatment for selected cases of low-risk small-size
breast cancer, professor Dr
·
Contents about Professor Dr
·
Contents about Professor Dr
·
Contents about Professor Dr
·
Contents about Professor Dr
·
Contents about Professor
Dr
·